image description

Tag: Roche

FDA Expedites Existing Drug Gazyva for Lupus Nephritis

September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus.  The FDA’s designation aims to  speed up  the development and review of drugs intended to treat a serious condition […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates